Acetazolamide and Heart attack - a phase IV clinical study of FDA data

Summary:

Heart attack is reported as a side effect among people who take Acetazolamide (acetazolamide), especially for people who are female, 60+ old, also take Fluconazole, and have Hiv infection.

The phase IV clinical study analyzes which people have Heart attack when taking Acetazolamide. It is created by eHealthMe based on reports of 5,933 people who have side effects when taking Acetazolamide from the FDA, and is updated regularly.

What is Acetazolamide?

Acetazolamide has active ingredients of acetazolamide. It is often used in pseudotumor cerebri. eHealthMe is studying from 6,179 Acetazolamide users. Check the latest studies of Acetazolamide.

What is Heart attack?

Heart attack is found to be associated with 2,475 drugs and 3,298 conditions by eHealthMe. Check the latest studies of Heart attack.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

5,933 people reported to have side effects when taking Acetazolamide.
Among them, 36 people (0.61%) have Heart attack.

Among these 36 people:

What is the gender of people who have Heart attack when taking Acetazolamide? *

female: 62.86 %
male: 37.14 %

What is the age of people who have Heart attack when taking Acetazolamide? *

What are other drugs people take besides Acetazolamide? *

What are other side effects people have besides Heart attack? *

Hypotension (abnormally low blood pressure): 5 people, 13.89%
Dyspnea (difficult or laboured breathing): 4 people, 11.11%
Acute Kidney Failure: 4 people, 11.11%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 4 people, 11.11%
Cardiac Failure Congestive: 4 people, 11.11%
Cardiac Failure: 3 people, 8.33%
Neuropathy Peripheral (surface nerve damage): 3 people, 8.33%
Lip And/or Oral Cavity Cancer (cancer of lip or mouth): 3 people, 8.33%
Multiple Allergies (allergy to multiple agents): 3 people, 8.33%
Carbon Dioxide Decreased: 2 people, 5.56%

What are the existing conditions these people have? *

Hiv Infection: 5 people, 13.89%
High Blood Pressure: 4 people, 11.11%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 3 people, 8.33%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 8.33%
Immunodeficiency Common Variable: 3 people, 8.33%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 5.56%
Primary Immunodeficiency Syndrome: 2 people, 5.56%
Lung Disorder (lung disease): 2 people, 5.56%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 5.56%
Cardiac Disorder: 2 people, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Acetazolamide and have Heart attack?

- Check whether Heart attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Acetazolamide:

Acetazolamide (6,179 reports)

Heart attack treatments and more:

Heart attack (266,145 reports)

Browse all side effects of Acetazolamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Heart attack:

Heart attack (2,475 drugs)

Browse all the conditions that are associated with Heart attack:

Heart attack (3,298 conditions)

Related publications that referenced our studies

Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .
Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on acetazolamide (the active ingredients of Acetazolamide) and Acetazolamide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.